EMA Considers Ways to Evaluate Non-Genotoxic Drug Impurities

Drug Industry Daily
A A
Drug sponsors should assess the safety of non-genotoxic impurities (NGIs) in chemically synthesized drugs on a case-by-case basis, the EMA’s Committee for Medicinal Products for Human Use suggests in a draft reflection paper released for stakeholder comment.

To View This Article:

Login

Subscribe To Drug Industry Daily